Co-Diagnostics (NASDAQ:CODX) Announces Quarterly Earnings Results, Misses Estimates By $12.75 EPS

by · The Markets Daily

Co-Diagnostics (NASDAQ:CODX – Get Free Report) released its earnings results on Tuesday. The company reported ($16.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.90) by ($12.75), FiscalAI reports. Co-Diagnostics had a negative return on equity of 70.26% and a negative net margin of 6,347.34%.The firm had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.13 million.

Here are the key takeaways from Co-Diagnostics’ conference call:

  • CoSara joint venture received a CDSCO license to manufacture the Kodiak PCR Pro in India and is expanding distribution to Bangladesh, Pakistan, Nepal and Sri Lanka while exploring strategic alternatives (including a potential SPAC) to access capital.
  • Co-Diagnostics is initiating TB clinical performance studies in India aligned with new WHO guidance (including tongue swab use) and expects commercialization of the TB test in India by Q3 2026.
  • The CoMira joint venture in Saudi Arabia is progressing toward local manufacturing (lease being finalized) and aims to be the first domestic molecular diagnostics manufacturer in the kingdom, supporting regional MENA expansion.
  • Financials show a decline in revenue to $0.6M in 2025, a $46.9M net loss (including an $18.9M impairment), cash down to $11.9M and ~$29M operating cash use, leaving the company dependent on additional financing and non-dilutive funding.
  • Co-Diagnostics strengthened its IP portfolio with recent patent grants covering core components of the Kodiak PCR platform in Australia and Japan, which may support future commercialization but has uncertain near-term impact.

Co-Diagnostics Trading Up 9.4%

NASDAQ:CODX traded up $0.16 during trading hours on Tuesday, hitting $1.86. 263,500 shares of the company traded hands, compared to its average volume of 3,521,331. Co-Diagnostics has a twelve month low of $1.66 and a twelve month high of $46.50. The firm has a 50-day moving average of $2.46 and a 200 day moving average of $7.44. The stock has a market capitalization of $3.91 million, a price-to-earnings ratio of -0.06 and a beta of 1.31.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on CODX shares. Wall Street Zen upgraded Co-Diagnostics from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Maxim Group lowered Co-Diagnostics from a “buy” rating to a “hold” rating in a report on Friday, January 23rd. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $67.50.

Check Out Our Latest Report on Co-Diagnostics

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CODX. Virtu Financial LLC raised its position in shares of Co-Diagnostics by 393.8% during the third quarter. Virtu Financial LLC now owns 126,524 shares of the company’s stock valued at $44,000 after buying an additional 100,901 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Co-Diagnostics by 314.1% in the second quarter. Jane Street Group LLC now owns 166,254 shares of the company’s stock valued at $47,000 after buying an additional 126,105 shares during the period. Finally, Geode Capital Management LLC grew its position in Co-Diagnostics by 40.4% during the fourth quarter. Geode Capital Management LLC now owns 449,148 shares of the company’s stock worth $81,000 after buying an additional 129,158 shares in the last quarter. Institutional investors own 14.99% of the company’s stock.

About Co-Diagnostics

(Get Free Report)

Co-Diagnostics, Inc is a molecular diagnostics company headquartered in Salt Lake City, Utah, known for its proprietary CoPrimer™ technology. Founded in 2016, the company focuses on the design, development and distribution of molecular diagnostic test kits for the detection of infectious diseases, genetic mutations and other health-relevant biomarkers. Its core platform leverages patented cooperative primers, which are engineered to enhance specificity, sensitivity and cost-effectiveness compared to conventional PCR-based assays.

Through its in-house manufacturing and global supply chain partnerships, Co-Diagnostics produces a range of real-time polymerase chain reaction (qPCR) kits, reagents and customized assay development services.

Featured Articles